AbbVie’s Blockbuster Vraylar Adds Significant Indication, Adjunctive MDD
Executive Summary
Already selling at a run rate above $2bn annually, AbbVie predicts the atypical antipsychotic could reach the $4bn mark with a new US indication for adjunctive treatment of major depressive disorder.
You may also be interested in...
AbbVie: Expect Smaller Deals Near-Term After 2023’s Big Finish
At the J.P. Morgan conference, AbbVie president Robert Michael said the company must effectively integrate ImmunoGen and Cerevel, which it expects to drive long-term growth.
AbbVie Gets Humira Erosion Right, But Skyrizi/Rinvoq Disappoint Investors
Humira’s US revenue declines by 26% as biosimilar adalimumab makes its debut. Follow-ons Skyrizi and Rinvoq post strong growth, but fall short of Street consensus estimates.
AbbVie: Competitor Pricing, Humira Formulary Placement Will Dictate US Biosimilars Impact
Now just months away from the first US Humira biosimilar launch, analysts are asking AbbVie for specifics on expected revenue erosion. CEO Gonzalez said AbbVie aims for 90% formulary coverage in 2023.